This article is more than 5 years old. Information may no longer be current.
Novo Nordisk pledges to ‘do our part’ for affordable diabetes drugs
Click Here to Manage Email Alerts
Novo Nordisk released a position statement on drug pricing and affordability, which included seeking collaborative solutions to make diabetes drugs affordable.
In response, the Endocrine Society applauded the pharmaceutical company’s position and expressed its hope that other players in the insulin supply chain would demonstrate similar commitment, according to a press release.
In its statement, Novo Nordisk said, “We recognize that people with diabetes are finding it harder to pay for their health care, including the medicines we make. As a company focused on improving the lives of people with diabetes, this is not acceptable. Ensuring access and affordability is a responsibility we share with all involved in health care, and we are going to do our part.”
Novo Nordisk endorsed a collaborative approach of all stakeholders — including pharmaceutical companies, payers, pharmacy benefit managers, insurance companies, employers, patient organizations and policy makers —to come up with a solution to rising drug prices.
The company set out three tenets for driving affordability:
Transforming the complex pricing system;
Creating more pricing predictability; and
Reducing the burden of out-of-pocket costs.
The Endocrine Society “believes that with greater transparency across the insulin supply chain, stakeholders can work together to make drug pricing more predictable, reduce out-of-pocket costs, and help patients and providers have access to affordable, patient-centered therapies.”